Home
About Us
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
Our Pipeline
Our pipeline emphasizes high value potential first-in-class biologics focused on dysregulated inflammation via the LIGHT-signaling network.
About the LIGHT-Signaling Network
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network).
Recent News
Dec 7, 2023 7:00 am
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
Nov 9, 2023 7:00 am
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
